Rituxan (Rituximab) (Genentech Inc. and Biogen Idec Inc.) for Chronic Lymphocytic Leukemia(CLL)
Record ID 32011000842
English
Authors' objectives:
Chronic lymphocytic leukemia (CLL) is a B-cell lineage lymphoid malignancy with an extremely variable course. According to the American Cancer Society, approximately 14,990 new cases of CLL and 4390 deaths from CLL occurred in the United States in 2010. CLL occurs primarily in middle-aged and elderly adults, with an average age at the time of diagnosis of 72 years. Although CLL is generally incurable, survival after diagnosis can range from months to decades. Most conventional first-line therapies for patients with CLL are noncurative and are only used to treat disease that is symptomatic or progressive.
Details
Project Status:
Completed
URL for project:
http://www.hayesinc.com
Year Published:
2011
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Antibodies, Monoclonal, Murine-Derived
- Leukemia, Lymphocytic, Chronic, B-Cell
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2011 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.